Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $9.51, for a total value of $108,860.97. Following the completion of the transaction, the director now directly owns 7,177,116 shares in the company, valued at $68,254,373.16. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Blake Borgeson also recently made the following trade(s):
- On Tuesday, June 11th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $8.45, for a total value of $96,727.15.
- On Tuesday, May 28th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $9.17, for a total value of $104,968.99.
- On Tuesday, April 30th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.95, for a total value of $91,003.65.
- On Tuesday, April 16th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.66, for a total value of $87,684.02.
- On Tuesday, April 2nd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $8.82, for a total value of $100,962.54.
Recursion Pharmaceuticals Stock Down 1.0 %
Shares of NASDAQ RXRX opened at $7.50 on Friday. Recursion Pharmaceuticals, Inc. has a 12 month low of $4.97 and a 12 month high of $16.75. The company has a market cap of $1.78 billion, a price-to-earnings ratio of -4.69 and a beta of 0.86. The business has a fifty day simple moving average of $8.84 and a 200-day simple moving average of $9.94.
Analyst Ratings Changes
Several research analysts recently weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $17.00 target price on shares of Recursion Pharmaceuticals in a research note on Tuesday, June 25th. KeyCorp upped their target price on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Monday, March 4th.
View Our Latest Stock Analysis on RXRX
Institutional Investors Weigh In On Recursion Pharmaceuticals
Several hedge funds have recently bought and sold shares of RXRX. Benjamin F. Edwards & Company Inc. purchased a new stake in Recursion Pharmaceuticals in the 1st quarter worth about $26,000. National Bank of Canada FI lifted its stake in Recursion Pharmaceuticals by 90.9% in the 4th quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock worth $31,000 after acquiring an additional 1,500 shares in the last quarter. First Horizon Advisors Inc. purchased a new stake in Recursion Pharmaceuticals in the 4th quarter worth about $47,000. QRG Capital Management Inc. purchased a new stake in Recursion Pharmaceuticals in the 3rd quarter worth about $86,000. Finally, Oxford Wealth Group LLC purchased a new stake in Recursion Pharmaceuticals in the 1st quarter worth about $106,000. 89.06% of the stock is owned by hedge funds and other institutional investors.
About Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Stories
- Five stocks we like better than Recursion Pharmaceuticals
- What is the Nikkei 225 index?
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- MarketBeat Week in Review – 6/24 – 6/28
- Why is the Ex-Dividend Date Significant to Investors?
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.